- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Can a State Sue Gilead Over the High Price of Its HCV Drugs?
What we're reading, January 28, 2016: Massachusetts' attorney general is threatening to sue Gilead Sciences over the high prices of its hepatitis C drugs; Anthem reports losses on Obamacare health plans; and consumers are satisfied with health coverage and limited networks.
In Massachusetts, the attorney general has warned Gilead Sciences that its high prices for Sovaldi and Harvoni may be illegal and violate the state’s law for fair trade practice. The Attorney general is not looking to sue the drugmaker for larger rebates or discounts, as others have done in the past, but for overpricing its products and violating consumer protection law, according to The Boston Globe.
UnitedHealth is not the only insurer feeling the pain from Affordable Care Act health plans. Now Anthem has announced that exchange plans caused the company to miss analyst expectations for fourth quarter earnings, reported Reuters. Anthem had enrolled 30% fewer beneficiaries than expected, which made the costs of running the business too high. However, Anthem CEO Joseph Swedish said enrollment data for 2016 so far looks a little better.
A new survey from Kaiser Family Foundation found that a majority of consumers don’t mind limited networks of doctors and hospitals to restrain prices and were satisfied with their coverage and the cost. However, people without insurance were less pleased and usually did not have coverage because they found it too expensive. In addition, healthcare is no longer a top priority for voters in the upcoming presidential election.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
